ReviewDrugs in context2018
Penile warts: an update on their evaluation and management.
Review in Drugs in context, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Heavy metal accumulation and its association with epididymal sperm morphometrics in dromedary camels with penile and preputial pathologies.Veterinary world · 2025Article
- Computer-assisted sperm analysis of the epididymal spermatozoa in dromedary camels suffering from penile and preputial pathological problems.Frontiers in veterinary science · 2025Article
- Review
- The Effectiveness of Chemical Cautery and Electrosurgery on Anogenital Wart: Systematic Review.Clinical, cosmetic and investigational dermatology · 2023Review
- Efficacy and Safety ofEvidence-based complementary and alternative medicine : eCAM · 2022Article
- Soluble Factors and Receptors Involved in Skin Innate Immunity-What Do We Know So Far?Biomedicines · 2021Review
- Verrucous herpes treated as condyloma acuminata: A case of cognitive bias.JAAD case reports · 2021Article
- Correlation of the ALA-PDT Treatment Efficacy and the HPV Genotype Profile of Genital Warts after Cryotherapy Failure and Podophyllotoxin Therapy in Male Patients.Life (Basel, Switzerland) · 2021Article
- Holmium:YAG Laser for the Treatment of Genital and urethral Warts: Multicentre Prospective Evaluation of Safety and Efficacy.Journal of lasers in medical sciences · 2021Article
- Coenzyme Q10, Zinc and MDA levels in verruca vulgarisTurkish journal of medical sciences · 2020Article
- Viral metagenomics updated the prevalence of human papillomavirus types in anogenital warts.Emerging microbes & infections · 2019Article
- Intralesional cidofovir for the management of refractory cutaneous verrucae: a review of applications and opportunities.Therapeutic advances in infectious diseaseReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPenile warts are the most common sexually transmitted disease in males. Clinicians should be familiar with the proper evaluation and management of this common condition.
objectiveTo provide an update on the current understanding, evaluation, and management of penile warts.
methodsA PubMed search was completed in Clinical Queries using the key terms 'penile warts' and 'genital warts'. The search strategy included meta-analyses, randomized controlled trials, clinical trials, observational studies, and reviews.
resultsPenile warts are caused by human papillomavirus (HPV), notably HPV-6 and HPV-11. Penile warts typically present as asymptomatic papules or plaques. Lesions may be filiform, exophytic, papillomatous, verrucous, hyperkeratotic, cerebriform, fungating, or cauliflower-like. Approximately one-third of penile warts regress without treatment and the average duration prior to resolution is approximately 9 months. Active treatment is preferable to watchful observation to speed up clearance of the lesions and to assuage fears of transmission and autoinoculation. Patient-administered therapies include podofilox (0.5%) solution or gel, imiquimod 3.75 or 5% cream, and sinecatechins (polypheron E) 15% ointment. Clinician-administered therapies include podophyllin, cryotherapy, bichloroacetic or trichloroacetic acid, oral cimetidine, surgical excision, electrocautery, and carbon dioxide laser therapy. Patients who do not respond to first-line treatments may respond to other therapies or a combination of treatment modalities. Second-line therapies include topical/intralesional/intravenous cidofovir, topical 5-fluorouracil, and topical ingenol mebutate.
conclusionNo single treatment has been shown to be consistently superior to other treatment modalities. The choice of the treatment method should depend on the physician's comfort level with the various treatment options, the patient's preference and tolerability of treatment, and the number and severity of lesions. The comparative efficacy, ease of administration, adverse effects, cost, and availability of the treatment modality should also be taken into consideration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.